JP2023517293A - 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用 - Google Patents

抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用 Download PDF

Info

Publication number
JP2023517293A
JP2023517293A JP2022552793A JP2022552793A JP2023517293A JP 2023517293 A JP2023517293 A JP 2023517293A JP 2022552793 A JP2022552793 A JP 2022552793A JP 2022552793 A JP2022552793 A JP 2022552793A JP 2023517293 A JP2023517293 A JP 2023517293A
Authority
JP
Japan
Prior art keywords
seq
xaa
amino acid
staple
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517293A5 (enExample
Inventor
ローレン ディー． ワレンスキー，
グレゴリー エイチ． バード，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2023517293A publication Critical patent/JP2023517293A/ja
Publication of JP2023517293A5 publication Critical patent/JP2023517293A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022552793A 2020-03-04 2021-03-04 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用 Pending JP2023517293A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985100P 2020-03-04 2020-03-04
US62/985,100 2020-03-04
PCT/US2021/020940 WO2021178714A2 (en) 2020-03-04 2021-03-04 ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2023517293A true JP2023517293A (ja) 2023-04-25
JP2023517293A5 JP2023517293A5 (enExample) 2024-09-12

Family

ID=75223491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552793A Pending JP2023517293A (ja) 2020-03-04 2021-03-04 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用

Country Status (8)

Country Link
US (1) US20240124529A1 (enExample)
EP (1) EP4114431A2 (enExample)
JP (1) JP2023517293A (enExample)
KR (1) KR20220148869A (enExample)
CN (1) CN115811984A (enExample)
AU (1) AU2021230544A1 (enExample)
CA (1) CA3173973A1 (enExample)
WO (1) WO2021178714A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297498A (en) * 2020-04-24 2022-12-01 Univ Columbia Lipid-peptide fusion inhibitors as sars-cov-2 antivirals
CN113817026B (zh) * 2021-09-16 2023-06-30 中国人民解放军海军军医大学 靶向刺突蛋白hr1的订书肽、制备方法及抗新型冠状病毒应用
CN113773370B (zh) * 2021-10-15 2022-07-22 哈尔滨吉象隆生物技术有限公司 一种抗病毒的多肽及其应用
CN118354791A (zh) * 2021-10-22 2024-07-16 威斯康星校友研究基金会 抑制导致新冠肺炎疾病的病毒sars-cov-2感染的肽
CN114437196A (zh) * 2022-02-16 2022-05-06 复旦大学 一种抑制SARS-CoV-2感染的蛋白及其用途
EP4611789A1 (en) * 2022-11-06 2025-09-10 Leyden Laboratories B.V. Sars-cov-2 binding polypeptide
EP4676938A2 (en) * 2023-03-08 2026-01-14 Dana-Farber Cancer Institute, Inc. Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
WO2025235945A1 (en) * 2024-05-10 2025-11-13 Red Queen Therapeutics, Inc. Methods of treating viral infections using a fusion inhibitor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity
US20060110758A1 (en) * 2004-11-22 2006-05-25 The University Of Hong Kong Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
JP2011510076A (ja) * 2008-01-23 2011-03-31 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
WO2011094357A2 (en) * 2010-01-26 2011-08-04 The Regents Of The University Of Colorado Conjugates utilizing platform technology for stimulating immune response
JP2012530720A (ja) * 2009-06-18 2012-12-06 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 構築されたウィルス性ペプチド組成物及び使用方法
JP2013530720A (ja) * 2010-07-19 2013-08-01 フィッシャー，アレクサンダー，ピー 植物栽培システムおよび方法
CN107022008A (zh) * 2016-01-30 2017-08-08 复旦大学 广谱地抑制人类冠状病毒感染的多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
WO2007005249A2 (en) * 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
WO2009137532A1 (en) * 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US9175047B2 (en) * 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
US20190048038A1 (en) 2016-02-23 2019-02-14 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
WO2019136824A1 (zh) * 2018-01-15 2019-07-18 中国人民解放军军事科学院军事医学研究院 抑制MERS-CoV感染的多肽

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity
US20060110758A1 (en) * 2004-11-22 2006-05-25 The University Of Hong Kong Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
JP2011510076A (ja) * 2008-01-23 2011-03-31 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
JP2012530720A (ja) * 2009-06-18 2012-12-06 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 構築されたウィルス性ペプチド組成物及び使用方法
WO2011094357A2 (en) * 2010-01-26 2011-08-04 The Regents Of The University Of Colorado Conjugates utilizing platform technology for stimulating immune response
JP2013530720A (ja) * 2010-07-19 2013-08-01 フィッシャー，アレクサンダー，ピー 植物栽培システムおよび方法
CN107022008A (zh) * 2016-01-30 2017-08-08 复旦大学 广谱地抑制人类冠状病毒感染的多肽及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREGORY H. BIRD ET AL.: ""Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptidetherapeutic"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 32, JPN6025009165, 21 July 2010 (2010-07-21), pages 14093 - 14098, ISSN: 0005542847 *

Also Published As

Publication number Publication date
CN115811984A (zh) 2023-03-17
WO2021178714A3 (en) 2022-02-17
WO2021178714A2 (en) 2021-09-10
EP4114431A2 (en) 2023-01-11
US20240124529A1 (en) 2024-04-18
KR20220148869A (ko) 2022-11-07
CA3173973A1 (en) 2021-09-10
AU2021230544A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JP2023517293A (ja) 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用
CA2862391C (en) Stabilized antiviral fusion helices
US20250084128A1 (en) ANTIVIRAL STRUCTURALLY-STAPLED SARS-CoV-2 PEPTIDE-CHOLESTEROL CONJUGATES AND USES THEREOF
EA017957B1 (ru) Композиции и способы, ингибирующие грипп
AU2021258205A1 (en) Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof
CA3193261A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
KR20230170918A (ko) 펩티드 및 펩티드를 포함하는 조성물
JP7854211B2 (ja) ヘマグルチニン結合ペプチド
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof
WO2024186980A2 (en) Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
US20250288658A1 (en) Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2022098848A1 (en) Antiviral structurally-stabilized ebolavirus peptides and uses thereof
CN117858889A (zh) 肽及包含肽的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260401